RPRX logo

Royalty Pharma (RPRX) EBIT

annual EBIT:

$1.56B-$330.95M(-17.54%)
December 31, 2024

Summary

  • As of today (July 3, 2025), RPRX annual earnings before interest & taxes is $1.56 billion, with the most recent change of -$330.95 million (-17.54%) on December 31, 2024.
  • During the last 3 years, RPRX annual EBIT has risen by +$148.98 million (+10.59%).
  • RPRX annual EBIT is now -42.99% below its all-time high of $2.73 billion, reached on December 31, 2019.

Performance

RPRX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

quarterly EBIT:

$498.69M+$98.58M(+24.64%)
March 31, 2025

Summary

  • As of today (July 3, 2025), RPRX quarterly earnings before interest & taxes is $498.69 million, with the most recent change of +$98.58 million (+24.64%) on March 31, 2025.
  • Over the past year, RPRX quarterly EBIT has increased by +$458.74 million (+1148.01%).
  • RPRX quarterly EBIT is now -66.97% below its all-time high of $1.51 billion, reached on December 31, 2019.

Performance

RPRX quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

TTM EBIT:

$2.02B+$458.74M(+29.48%)
March 31, 2025

Summary

  • As of today (July 3, 2025), RPRX TTM earnings before interest & taxes is $2.02 billion, with the most recent change of +$458.74 million (+29.48%) on March 31, 2025.
  • Over the past year, RPRX TTM EBIT has increased by +$643.87 million (+46.96%).
  • RPRX TTM EBIT is now -32.03% below its all-time high of $2.96 billion, reached on September 30, 2020.

Performance

RPRX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

RPRX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-17.5%+1148.0%+47.0%
3 y3 years+10.6%+184.7%+45.4%
5 y5 years-43.0%+206.6%-28.5%

RPRX EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-17.5%+272.3%-42.9%+188.6%at high+382.0%
5 y5-year-43.0%+272.3%-42.9%+188.6%-32.0%+382.0%
alltimeall time-43.0%+272.3%-67.0%+188.6%-32.0%+382.0%

RPRX EBIT History

DateAnnualQuarterlyTTM
Mar 2025
-
$498.69M(+24.6%)
$2.02B(+29.5%)
Dec 2024
$1.56B(-17.5%)
$400.11M(-54.2%)
$1.56B(-19.0%)
Sep 2024
-
$872.86M(+258.6%)
$1.92B(+57.9%)
Jun 2024
-
$243.39M(+509.1%)
$1.22B(-11.3%)
Mar 2024
-
$39.96M(-94.8%)
$1.37B(-27.3%)
Dec 2023
$1.89B(+351.5%)
$764.84M(+355.0%)
$1.89B(+237.4%)
Sep 2023
-
$168.11M(-57.8%)
$559.36M(-15.1%)
Jun 2023
-
$398.29M(-28.4%)
$658.64M(-17.6%)
Mar 2023
-
$556.04M(-198.8%)
$798.92M(+91.1%)
Dec 2022
$418.02M(-70.3%)
-$563.08M(-310.6%)
$418.02M(-61.4%)
Sep 2022
-
$267.39M(-50.4%)
$1.08B(+0.1%)
Jun 2022
-
$538.56M(+207.5%)
$1.08B(-22.0%)
Mar 2022
-
$175.15M(+74.0%)
$1.39B(-1.5%)
DateAnnualQuarterlyTTM
Dec 2021
$1.41B(-24.3%)
$100.64M(-62.2%)
$1.41B(-17.8%)
Sep 2021
-
$266.12M(-68.5%)
$1.71B(-18.5%)
Jun 2021
-
$844.18M(+329.8%)
$2.10B(+11.0%)
Mar 2021
-
$196.39M(-51.4%)
$1.89B(+1.8%)
Dec 2020
$1.86B(-31.9%)
$404.47M(-38.3%)
$1.86B(-37.3%)
Sep 2020
-
$655.70M(+3.1%)
$2.96B(+5.2%)
Jun 2020
-
$636.16M(+291.1%)
$2.82B(+16.0%)
Mar 2020
-
$162.68M(-89.2%)
$2.43B(-11.0%)
Dec 2019
$2.73B(+51.9%)
$1.51B(+196.7%)
$2.73B(+123.7%)
Sep 2019
-
$508.82M(+105.2%)
$1.22B(+71.5%)
Jun 2019
-
$247.94M(-46.5%)
$711.30M(+53.5%)
Mar 2019
-
$463.36M
$463.36M
Dec 2018
$1.80B(+13.0%)
-
-
Dec 2017
$1.59B
-
-

FAQ

  • What is Royalty Pharma annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Royalty Pharma?
  • What is Royalty Pharma annual EBIT year-on-year change?
  • What is Royalty Pharma quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Royalty Pharma?
  • What is Royalty Pharma quarterly EBIT year-on-year change?
  • What is Royalty Pharma TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Royalty Pharma?
  • What is Royalty Pharma TTM EBIT year-on-year change?

What is Royalty Pharma annual earnings before interest & taxes?

The current annual EBIT of RPRX is $1.56B

What is the all time high annual EBIT for Royalty Pharma?

Royalty Pharma all-time high annual earnings before interest & taxes is $2.73B

What is Royalty Pharma annual EBIT year-on-year change?

Over the past year, RPRX annual earnings before interest & taxes has changed by -$330.95M (-17.54%)

What is Royalty Pharma quarterly earnings before interest & taxes?

The current quarterly EBIT of RPRX is $498.69M

What is the all time high quarterly EBIT for Royalty Pharma?

Royalty Pharma all-time high quarterly earnings before interest & taxes is $1.51B

What is Royalty Pharma quarterly EBIT year-on-year change?

Over the past year, RPRX quarterly earnings before interest & taxes has changed by +$458.74M (+1148.01%)

What is Royalty Pharma TTM earnings before interest & taxes?

The current TTM EBIT of RPRX is $2.02B

What is the all time high TTM EBIT for Royalty Pharma?

Royalty Pharma all-time high TTM earnings before interest & taxes is $2.96B

What is Royalty Pharma TTM EBIT year-on-year change?

Over the past year, RPRX TTM earnings before interest & taxes has changed by +$643.87M (+46.96%)
On this page